SV

Street Verdict

Analyst Scorecard

MOLBIO · NSE

Molbio Diagnostics Limited

₹1,495.5

-2.02% (-₹30.9)

Prev. close

₹1,526.4

Volume

7,00,865

Delivery %

18.5%

As of

20 Nov 2026

Price history

₹1,495.5+₹384.6 (+34.62%) · 3M
18 Aug 2026 → 20 Nov 2026
1,1001,2001,3001,4001,50018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

Analysts lean bullish

1 analyst stance · last 90 days · one per analyst

Trackable

1 · 1 bull / 0 neutral / 0 bear

Long-Horizon

none in range

Commentary

none in range

Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded

Bullish 100% (1)Neutral 0% (0)Bearish 0% (0)
Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions

Fundamentals

About Molbio Diagnostics Limited

Molbio Diagnostics Limited, a point-of-care diagnostics company, provides healthcare technologies to diagnose infectious and non-communicable diseases. It manufactures and sells chip based diagnostic devices, chips and reagents, X-ray equipment's, and single/dual detectors. It also offers disposable POCT devices, which includes dengue, malaria, and COVID-19 tests; Tabletop analysers, a portable machine that are used to perform molecular or immunodiagnostic tests to detect infectious diseases, such as tuberculosis, human papillomavrus, STIs, and GI disorders. In addition, the company offers Truenat, a multi-disease real-time polymerase chain reaction platform that enables treatment decisions for various infectious and non-communicable diseases, such as tuberculosis, human immunodeficiency virus, malaria, viral hepatitis, COVID-19, dengue, chikungunya, influenza, H1N1, HPV/cervical cancer, cholera, leprosy, etc.; and Truenat assays. The company was incorporated in 2000 and is based in Verna, India.

Details

Sector

Healthcare

Industry

Medical Devices

CEO

Mr. Sriram Natarajan

Headquarters

Verna

Employees

1,225

Key stats

Market cap

₹15,923.86 Cr

P/E ratio (TTM)

95.6

Dividend yield

0.00%

EPS (TTM)

₹14.46

Shares float

88.57 L

EPS · quarter ended Jun 2026

₹5.10

Financial Performance

01 · Financials

-1000 Cr0 Cr1000 Cr2000 Cr₹-10%0%10%20%FY23FY24FY25FY26
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

-1001020₹FY23FY24FY25FY26

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based · pre-FY23 not filed in verifiable form

-100%0%100%200%FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

Pre-FY23 not filed in verifiable form

0 Cr1000 Cr2000 Cr3000 Cr₹0×0.2×0.4×0.6×0.8×FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

Pre-FY23 not filed in verifiable form

0 Cr1000 Cr2000 Cr3000 Cr₹FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

Pre-FY23 not filed in verifiable form

-250 Cr0 Cr250 Cr500 Cr₹FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY23FY24FY25FY26
₹322.43 Cr₹819.73 Cr₹997.48 Cr₹1,414.96 Cr
EBITDA
₹47.91 Cr₹184.34 Cr₹254.99 Cr₹326.17 Cr
₹-72.60 L₹101.95 Cr₹145.10 Cr₹166.59 Cr
Diluted EPS
₹-0.06₹8.85₹12.59₹14.46

09 · Balance Sheet

Annual

Line itemFY23FY24FY25FY26
₹1,034.21 Cr₹1,221.06 Cr₹1,461.56 Cr₹2,148.42 Cr
₹118.54 Cr₹183.63 Cr₹146.93 Cr₹450.08 Cr
Stockholders' equity
₹721.48 Cr₹823.38 Cr₹968.39 Cr₹1,169.34 Cr

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY23FY24FY25FY26
₹64.13 Cr₹9.57 Cr₹287.10 Cr₹50.39 Cr
Investing cash flow
₹-39.73 Cr₹-45.01 Cr₹-122.65 Cr₹-93.22 Cr
₹18.24 Cr₹-31.55 Cr₹-26.15 Cr₹276.07 Cr
Capital expenditure
₹-14.50 Cr₹-16.11 Cr₹-54.66 Cr₹-50.02 Cr
End cash position
₹-8.08 Cr₹-75.07 Cr₹63.23 Cr₹335.77 Cr

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemAug 26
Promoter41.29%
Public58.71%
Employee trusts0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Molbio Diagnostics Limited₹15,566.62 Cr₹1,350.893.413.3114.2%0.38+41.9%—

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.

MOLBIO

Apollo Hospitals, Aster or Molbio — which is a better bet as healthcare stocks rally up to 4% despite D-Street weakness?

Livemint · 3 days ago

MOLBIO

Molbio Diagnostics (NSE:MOLBIO) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Molbio Diagnostics reported FY ending September 2026 profit of ₹1.54 billion while generating ₹4.0 billion free cash flow, resulting in a negative accrual ratio of –0.19 that suggests cash generation exceeds reported earnings. The strong cash position and rising EPS have not yet moved the share price, highlighting a disconnect between the earnings release and market reaction.